SPI and Neuralstem sign licensing agreement for major depression drug, NSI-189

Neuralstem, Inc. (NYSE Amex: CUR) announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan (SPI), a wholly owned subsidiary of Sumitomo Corporation Group.  Under the agreement, SPI will market development and licensing rights to NSI-189, Neuralstem's neurogenic compound, currently in an FDA-approved Phase I clinical trial for major depression.  

"We have stated previously our intention to take NSI-189 through Phase II trials before seeking a partner for worldwide rights," said Neuralstem President & CEO Richard Garr. "The single exception to this strategy is the Japanese market, where we are aggressively seeking an early-stage development and licensing partner. We look forward to working with Sumitomo to achieve this end."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Depression impacts survival rates and quality of life for women with breast cancer